Qibai Pingfei Capsule ameliorates NK‑cell dysfunction in COPD: Insights from single‑cell sequencing in a randomized multicenter double‑blinded placebo‑controlled trial.
Mengyao Shi, Lu Zhang, Siyu Tang et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, double-blind, placebo-controlled, multicenter trial investigated the effects of Qibai Pingfei Capsule (QBPF) on chronic obstructive pulmonary disease (COPD) patients. The study found that QBPF significantly decreased acute exacerbation frequency (p = 0.042) and improved CAT scores (p = 0.008), while enhancing NK cell activity, suggesting a potential mechanism for its therapeutic effects in COPD management.
Key findings
- Acute exacerbation frequency decreased significantly with QBPF treatment (p = 0.042).
- CAT scores improved significantly in the QBPF group (p = 0.008).
- The 6-minute walk test showed significant improvement from baseline to 3 months (p < 0.01).
- QBPF modulated NK cell function, enhancing activity in COPD patients.
Why it matters
Understanding the mechanisms by which traditional Chinese medicine like QBPF can improve immune function in COPD may offer new therapeutic strategies. This could enhance patient management and outcomes in a condition characterized by chronic inflammation and immune dysfunction.